Food Producer Adds 46% to Dividend

Hello and welcome to Dividend Brief, the 2 times weekly newsletter focused on dividend investing.

Today, we will look into Eli Lilly, Pfizer, and Apple, highlight a few dividend stocks worth watching, as well as share companies that are about to pay a dividend in the next few days.

Crypto Market

Could These “Trump Coins” Spark the Next Crypto Boom?

Back in 2017, President Trump’s inauguration marked the start of a historic crypto surge, turning modest investments into extraordinary gains. Coins like Monero, Stellar, and ReddCoin delivered life-changing returns for those who acted early.

Now, as America prepares for its first pro-crypto president, the stage is set for another potential breakthrough. Tech expert Jeff Brown believes this moment could redefine the crypto market and create unprecedented opportunities for investors.

Jeff has identified specific “Trump coins” he believes are poised to soar under the new administration, with one in particular that could deliver exponential returns.

Click here to uncover the “Trump coins” to watch now and automatically RSVP.

Crypto Market

Could These “Trump Coins” Spark the Next Crypto Boom?

Back in 2017, President Trump’s inauguration marked the start of a historic crypto surge, turning modest investments into extraordinary gains. Coins like Monero, Stellar, and ReddCoin delivered life-changing returns for those who acted early.

Now, as America prepares for its first pro-crypto president, the stage is set for another potential breakthrough. Tech expert Jeff Brown believes this moment could redefine the crypto market and create unprecedented opportunities for investors.

Jeff has identified specific “Trump coins” he believes are poised to soar under the new administration, with one in particular that could deliver exponential returns.

Click here to save your seat and uncover the “Trump coins” to watch now

Healthcare

Eli Lilly Advances Alzheimer’s Drug Development in Competitive Market

Eli Lilly is emerging as a key player in the evolving landscape of Alzheimer’s treatment, with its focus on innovative therapies poised to shape the market in 2025. The company's recent strides, particularly with its Kisunla treatment, which received FDA approval in mid-2024, are garnering significant attention. Kisunla works to slow the progression of Alzheimer’s by targeting brain amyloid levels in early-stage patients. However, like other treatments, it does not halt or reverse the disease and comes with potential side effects such as brain swelling and bleeding.

Building on this momentum, Eli Lilly is advancing its next-generation drug, remternetug, currently in late-stage trials. This new formulation is being evaluated for its effectiveness in clearing amyloid plaques and ensuring patient safety. Analysts anticipate trial results could emerge by late 2025 or early 2026, potentially offering a more effective treatment option.

As competition in this space intensifies, with other companies also investing heavily in Alzheimer's research, Eli Lilly’s progress could set the tone for its standing in this multi-billion-dollar market. The coming year will be pivotal in determining how its treatments perform in terms of patient adoption and clinical outcomes, potentially solidifying its leadership in this critical therapeutic area.

LLY currently trades at $799 and pays a dividend of $1.50 per share, a yield of 0.76%.

Healthcare

Pfizer Announces Positive Trial Results for Sasanlimab in Bladder Cancer Treatment

Pfizer recently announced that its late-stage trial of sasanlimab, used in combination with Bacillus Calmette-Guérin (BCG) as an induction therapy, has met its primary goal in treating high-risk non-muscle invasive bladder cancer in patients who have not previously received BCG treatment. The trial showed a statistically significant and clinically meaningful improvement when sasanlimab was combined with BCG compared to using BCG alone.

The safety profile of the combination was in line with expectations, reflecting the known safety of BCG and the data from previous sasanlimab trials. This outcome also aligns with the typical safety profile observed in other PD-1 inhibitors.

In addition to its work with BCG, sasanlimab is being explored in other cancer treatments, including combinations with Pfizer’s antibody-drug conjugates for advanced solid tumors. These ongoing investigations aim to expand the potential applications of sasanlimab in oncology, offering promising new approaches to treating various forms of cancer.

PFE currently trades at $27 and pays a dividend of 43 cents per share, a yield of 6.40%.

Income Made Simple

Turn Affordable Stocks Into a Monthly Income Stream

Imagine turning low-cost stocks into a reliable monthly paycheck. It’s not just possible—it’s within reach. With a proven strategy designed for steady income, you could generate consistent returns from affordable stocks like Intel and Ford.

This approach leverages techniques that minimize risk while enhancing your portfolio’s earning potential, making it ideal for traders seeking stability and growth.

Unlock the details in our free report: "How to Collect a Rent Paycheck Each Month on Affordable Stocks." It’s your guide to transforming your investment strategy and creating a dependable income stream.

Click here to access the report and start building your income today.

By following the link above or using any of the links provided below, you're choosing to opt in to receive insightful updates from Wealthiest Investor News + 2 free bonus subscriptions! Your privacy is important to us. You can unsubscribe anytime. See our privacy policy for details. See our privacy policy for details)

Tech

Apple Rejects Claims of Using Siri Data for Ads

Apple has addressed recent rumors suggesting Siri data was used for advertising purposes. The company firmly denies ever utilizing Siri recordings to create marketing profiles, share with advertisers, or sell to third parties. In a statement, Apple emphasized its ongoing commitment to enhancing user privacy through evolving technologies.

These claims gained attention following Apple’s $95 million settlement to resolve allegations related to Siri capturing conversations. Reports from past lawsuits revealed that anonymized audio recordings were occasionally reviewed by human contractors to improve Siri’s accuracy, but there’s no evidence linking these recordings to targeted advertising. Apple had already revised its policies in 2019, making Siri interactions opt-in for data retention and ensuring recordings are not shared with external contractors.

While speculation persists, privacy experts point to alternative explanations for ad targeting. Data networks often leverage shared device information, location tracking, or app usage to infer consumer interests. This includes data collected by brokers and tech platforms building profiles from third-party sources.

These practices highlight the broader concerns surrounding digital privacy and data tracking. For users seeking greater control, disabling certain settings and reviewing app permissions can mitigate some of these risks.

As the debate over privacy continues, the spotlight remains on companies to maintain transparency and safeguard user data.

AAPL currently trades at $236 and pays a dividend of 25 cents per share, a yield of 0.41%.

CALM increased its dividend payout to $1.49 per share, an increase of 46%. Its new forward yield is 3.9%.

PAA upped its dividend payout to 38 cents per share, an increase of 19%. Its new forward yield is 6.8%.

JEF boosted its dividend payout to 40 cents per share, an increase of 14%. Its new forward yield is 2.0%.

HSHP lowered its dividend payout to 0.5 cents per share, a cut of 50%. Its new dividend yield is 1.21%.

MMT dropped its dividend payout to 3 cents per share, a cut of 0.06%. Its new dividend yield is 8.7%.

MVO decreased its dividend payout to 24 cents per share, a cut of 27%. Its new dividend yield is 15.6%.